GBR 900

Drug Profile

GBR 900

Alternative Names: BXL-1H5; GBR-900; MNAC-13

Latest Information Update: 06 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lay Line Genomics
  • Developer Glenmark Pharmaceuticals S.A.
  • Class Analgesics; Monoclonal antibodies
  • Mechanism of Action TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 01 Nov 2016 Glenmark Pharmaceuticals completes a phase I trial in Pain (In volunteers) in United Kingdom (NCT02235727)
  • 04 Jun 2014 Phase-I clinical trials in Pain in United Kingdom (Parenteral)
  • 29 Apr 2014 Glenmark Pharmaceuticals files a Clinical Trial Application with the Medicines and Healthcare Products Regulatory Agency in the United Kingdom for Pain
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top